Evidence map›Paper›PMID 41903651›Full record

ArticleMolecular & cellular proteomics : MCP2026

Identification of MHC Ligands Through Allele-Guided Isolation Combined With Machine Learning for Improved MHC Assignment Using ARDisplay-I.

Shima Mecklenbräuker, Piotr Skoczylas, Paweł Biernat, Badeel Kh Q Zaghla, Bilge Atay, Mai Hossam, Bartłomiej Król-Józaga, Maciej Jasiński, Victor Murcia Pienkowski, Anna Sanecka-Duin and 8 more

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shima MecklenbräukerDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité- University Medicine Berlin, Berlin, Germany.
Piotr SkoczylasArdigen S.A., Krakow, Poland.
Paweł BiernatArdigen S.A., Krakow, Poland.
Badeel Kh Q ZaghlaDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité- University Medicine Berlin, Berlin, Germany.
Bilge AtayDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité- University Medicine Berlin, Berlin, Germany.
Mai HossamDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité- University Medicine Berlin, Berlin, Germany.
Bartłomiej Król-JózagaArdigen S.A., Krakow, Poland.
Maciej JasińskiArdigen S.A., Krakow, Poland.
Victor Murcia PienkowskiAix Marseille Univ, INSERM, Marseille Medical Genetics, MMG, Marseille, France.
Anna Sanecka-DuinArdigen S.A., Krakow, Poland.
Oliver PoppMax-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany.
Mohamed HajiMax-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany.
Rafał SzatanekArdigen S.A., Krakow, Poland.
Philipp MertinsMax-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Jan KaczmarczykArdigen S.A., Krakow, Poland. Electronic address: jan.kaczmarczyk@ardigen.com.
Ulrich KellerDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité- University Medicine Berlin, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Germany.
Agnieszka BlumArdigen S.A., Krakow, Poland.
Martin G KlattDepartment of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité- University Medicine Berlin, Berlin, Germany; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany. Electronic address: martin.klatt@charite.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The isolation of major histocompatibility complex (MHC) ligands and subsequent analysis by mass spectrometry is considered the gold standard for defining targets for T cell-based immunotherapies. However, as many targets of high tumor specificity are only presented at low abundance on the cell surface of tumor cells, the efficient isolation of these peptides is crucial for their successful detection. Here, we demonstrate how optimizing the MHC ligand isolation strategy, based on both the presenting MHC alleles and the individual peptide level, enhances the identification of specific MHC ligands. This ideally acknowledges not only the hydrophobicity but also the post-translational modifications of the respective MHC ligands. To further improve the identification and characterization of MHC ligands, we developed an MHC class I ligand prediction algorithm (ARDisplay-I) that outperforms current state-of-the-art tools when benchmarked against competitors such as netMHCpan 4.1, MixMHCpred, or MHCflurry. Implementing these strategies can augment the development of T cell receptor-based therapies by improving the identification of novel immunotherapy targets and enriching the resources available in the computational immunology field through a superior MHC presentation prediction algorithm.

Indexed as

Histocompatibility Antigens Class IMachine LearningAlgorithmsAllelesHumansImmunoinformaticsLigandsPeptidesPrediction AlgorithmsHistocompatibility Antigens Class ILigandsPeptidesHLA ligand isolationimmunopeptidomicsmachine learningmultiallelic datapost-translational modifications

Identifiers

PMID41903651
PMCPMC13156753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.